Theravance Biopharma (TBPH) Finished Goods (2013 - 2018)

Theravance Biopharma (TBPH) has 6 years of Finished Goods data on file, last reported at $3.5 million in Q3 2018.

• Finished Goods for Q3 2018 came in at $3.5 million, down 22.92% year-over-year; the trailing twelve-month figure through Sep 2018 was $3.5 million (down 22.92% YoY), and the FY2017 annual result was $5.0 million, up 42.8% from the prior year.
• Finished Goods slipped to $3.5 million in Q3 2018 per TBPH's latest filing, from $4.0 million in the prior quarter.
• Over five years, Finished Goods peaked at $7.5 million in Q3 2014 and troughed at $2.0 million in Q2 2017.
• A 5-year average of $4.3 million and a median of $4.6 million in 2017 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2016 and 2018: Finished Goods slumped 58.75% in 2016, then soared 99.6% in 2018.
• A 5-year view of Finished Goods shows it stood at $5.6 million in 2014, then sank by 43.71% to $3.1 million in 2015, then advanced by 12.44% to $3.5 million in 2016, then jumped by 42.8% to $5.0 million in 2017, then plunged by 30.29% to $3.5 million in 2018.
• Business Quant data shows TBPH's Finished Goods at $3.5 million in Q3 2018, $4.0 million in Q2 2018, and $4.6 million in Q1 2018.